An investor consortium led an additional $55m funding in Series B2 round in Enveda Biosciences, a biotechnology company using AI to translate nature into new medicines, with participation from Premji Invest, Lingotto Investment Fund, Microsoft, The Nature Conservancy, Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners. “The investors who joined in this round recognize our rapid progress, as well as our expansive potential and vision. In combination with our deep bench of top tier investors, we are in an ideal position to advance our novel medicines into the clinic and to bring hope to waiting patients,” Viswa Colluru, Enveda CEO and Founder.